TIKLOPIDIN (Ticlopidine) *. 5-[(2-Hlorfenil) methyl-4, 5, 6, 7-tetragidrotieno [3, 2-c] pyridine.

     C inonimy : Tiklid, Angregal, Caudalin, Iriflexin, Panaldine, Ticlid, Ticlidan, Ticlopin, Ticlosan, Tilcid.

     The new medicine, which is considered "clean" (electoral) antiagregantom, far surpassing the reality atsetilsalitsilovuyu acid.

     Tiklopidin ingibiruet aggregation and adgezivnost platelets and erythrocyte has dezagregatsionnoe effect, promotes education prostaglandines E 1 and D 2 and prostatsiklina, improves.

     Tiklopidin applied for the prevention of brain in ischaemic cerebrovascular disease, coronary artery disease, post-myocardial infarction, with ischaemic limbs diseases associated with vascular ateroskleroticheskimi changes in retinopathy in patients with diabetes mellitus, to prevent tromboobrazovaniya after shunting blood vessels.

     There are also positive results when applying tiklopidina in patients posttromboticheskoy retinopathy.

     Assign food inside at the time of 0,25 g (250 mg) two times a day. Adopt appropriate and good endurance of long-term (2-6 months or more).

     In applying tiklopidina could experience diarrhea, pain in the stomach, skin, allergic reactions, dizziness, in some cases, jaundice.

     There hemorrhagic phenomena trombopeniya, radiation, agranulotsitoz. In the treatment process must be systematically haematology research and monitoring functions of the liver. Do not assign the same time as anti-drug and other antiagregantami (acetylsalicylic acid, etc.).

     The drug is contraindicated in patients at risk of bleeding, with worsening stomach ulcer and duodenal ulcers, acute hemorrhagic stroke, liver diseases, pregnancy and breastfeeding.

     Form-release tablets of 0.25 g.

Materials allowed to copy only with the active hyperlink to the handbook of medicines